{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T21:38:50Z","timestamp":1788730730262,"version":"build-2803163510"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>While \u03b2-blockers are associated with decreased mortality in cardiovascular disease (CVD), exacerbation-prone patients with chronic obstructive pulmonary disease (COPD) who received metoprolol in the Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (BLOCK-COPD) trial experienced increased risk of exacerbations requiring hospitalization. However, the study excluded individuals with established indications for the drug, raising questions about the overall risk and benefit in patients with COPD following acute myocardial infarction (AMI).<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate whether \u03b2-blocker prescription at hospital discharge is associated with increased risk of mortality or adverse cardiopulmonary outcomes in patients with COPD and AMI.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This prospective, longitudinal cohort study with 6 months of follow-up enrolled patients aged 35 years or older with COPD who underwent cardiac catheterization for AMI at 18 BLOCK-COPD network hospitals in the US from June 2020 through May 2022.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Prescription for any \u03b2-blocker at hospital discharge.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was time to the composite outcome of death or all-cause hospitalization or revascularization. Secondary outcomes included death, hospitalization, or revascularization for CVD events, death or hospitalization for COPD or respiratory events, and treatment for COPD exacerbations.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 3531 patients who underwent cardiac catheterization for AMI, prevalence of COPD was 17.1% (95% CI, 15.8%-18.4%). Of 579 total patients with COPD and AMI, 502 (86.7%) were prescribed a \u03b2-blocker at discharge. Among the 562 patients with COPD included in the final analysis, median age was 70.0 years (range, 38.0-94.0 years) and 329 (58.5%) were male; 553 of the 579 patients (95.5%) had follow-up information. Among those discharged with \u03b2-blockers, there was no increased risk of the primary end point of all-cause mortality, revascularization, or hospitalization (hazard ratio [HR], 1.01; 95% CI, 0.66-1.54; P<\/jats:italic>\u2009=\u2009.96) or of cardiovascular events (HR, 1.11; 95% CI, 0.65-1.92; P<\/jats:italic>\u2009=\u2009.69), COPD-related or respiratory events (HR, 0.75; 95% CI, 0.34-1.66; P<\/jats:italic>\u2009=\u2009.48), or treatment for COPD exacerbations (rate ratio, 1.01; 95% CI, 0.53-1.91; P<\/jats:italic>\u2009=\u2009.98).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study, \u03b2-blocker prescription at hospital discharge was not associated with increased risk of adverse outcomes in patients with COPD and AMI. These findings support use of \u03b2-blockers in patients with COPD and recent AMI.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.7535","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T15:07:20Z","timestamp":1716304040000},"page":"e247535","source":"Crossref","is-referenced-by-count":9,"title":["\u03b2-Blocker Use and Clinical Outcomes in Patients With COPD Following Acute Myocardial Infarction"],"prefix":"10.1001","volume":"7","author":[{"given":"David C.","family":"LaFon","sequence":"first","affiliation":[{"name":"Division of Pulmonary, Allergy and Critical Care Medicine, Heersink School of Medicine, The University of Alabama at Birmingham"},{"name":"UAB Lung Health Center, Heersink School of Medicine, The University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika S.","family":"Helgeson","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Health Data Science, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lindberg","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Health Data Science, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Voelker","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Health Data Science, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya P.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy and Critical Care Medicine, Heersink School of Medicine, The University of Alabama at Birmingham"},{"name":"UAB Lung Health Center, Heersink School of Medicine, The University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Casaburi","sequence":"additional","affiliation":[{"name":"Lundquist Institute for Biomedical Innovation, Harbor\u2013UCLA Medical Center, Torrance, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Cassady","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, University of Maryland, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Connett","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Health Data Science, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard J.","family":"Criner","sequence":"additional","affiliation":[{"name":"Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umur","family":"Hatipoglu","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Kaminsky","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Medicine, University of Vermont, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken M.","family":"Kunisaki","sequence":"additional","affiliation":[{"name":"Minneapolis VA Health Care System, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Lazarus","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, University of California San Francisco"},{"name":"Cardiovascular Research Institute, University of California San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene E.","family":"McEvoy","sequence":"additional","affiliation":[{"name":"Health Partners Institute, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Reed","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, University of Maryland, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank C.","family":"Sciurba","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Stringer","sequence":"additional","affiliation":[{"name":"Lundquist Institute for Biomedical Innovation, Harbor\u2013UCLA Medical Center, Torrance, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Dransfield","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy and Critical Care Medicine, Heersink School of Medicine, The University of Alabama at Birmingham"},{"name":"UAB Lung Health Center, Heersink School of Medicine, The University of Alabama at Birmingham"},{"name":"Birmingham VA Medical Center, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"issue":"10159","key":"zoi240285r1","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017.","volume":"392","author":"GBD 2017 Causes of Death Collaborators","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"zoi240285r2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.trsl.2013.05.001","article-title":"Chronic obstructive pulmonary disease and cardiovascular disease.","volume":"162","author":"Bhatt","year":"2013","journal-title":"Transl Res"},{"issue":"8","key":"zoi240285r3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S2213-2600(15)00241-6","article-title":"Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.","volume":"3","author":"Chen","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"8251","key":"zoi240285r4","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S0140-6736(81)91101-6","article-title":"Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial.","volume":"2","author":"Hjalmarson","year":"1981","journal-title":"Lancet"},{"issue":"8","key":"zoi240285r5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1056\/NEJM199808203390801","article-title":"Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction.","volume":"339","author":"Gottlieb","year":"1998","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi240285r6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/thoraxjnl-2015-207251","article-title":"\u00df-Blockers are associated with a reduction in COPD exacerbations.","volume":"71","author":"Bhatt","year":"2016","journal-title":"Thorax"},{"issue":"11","key":"zoi240285r7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113048","article-title":"Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies.","volume":"9","author":"Du","year":"2014","journal-title":"PLoS One"},{"key":"zoi240285r8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1471-2466-12-48","article-title":"Beta-blocker use and COPD mortality: a systematic review and meta-analysis.","volume":"12","author":"Etminan","year":"2012","journal-title":"BMC Pulm Med"},{"issue":"12","key":"zoi240285r9","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1016\/j.jacc.2006.04.039","article-title":"Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease.","volume":"47","author":"Mancini","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"zoi240285r10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213187","article-title":"\u00df-Blockers after acute myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide population-based observational study.","volume":"14","author":"Su","year":"2019","journal-title":"PLoS One"},{"issue":"24","key":"zoi240285r11","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1056\/NEJMoa1908142","article-title":"Metoprolol for the prevention of acute exacerbations of COPD.","volume":"381","author":"Dransfield","year":"2019","journal-title":"N Engl J Med"},{"issue":"14","key":"zoi240285r12","doi-asserted-by":"publisher","first-page":"3G","DOI":"10.1016\/0002-9149(85)90689-7","article-title":"Metoprolol in acute myocardial infarction: patients and methods.","volume":"56","author":"The MIAMI Trial Research Group","year":"1985","journal-title":"Am J Cardiol"},{"issue":"9B","key":"zoi240285r13","doi-asserted-by":"publisher","first-page":"54J","DOI":"10.1016\/S0002-9149(97)00841-2","article-title":"Rationale, design, and organization of the Metoprolol CR\/XL Randomized Intervention Trial in Heart Failure (MERIT-HF).","volume":"80","author":"The International Steering Committee","year":"1997","journal-title":"Am J Cardiol"},{"issue":"7","key":"zoi240285r14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/qjmed\/hci080","article-title":"Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease.","volume":"98","author":"Egred","year":"2005","journal-title":"QJM"},{"issue":"5","key":"zoi240285r15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1080\/15412555.2018.1554637","article-title":"Beta-blockers in COPD: a methodological review of the observational studies.","volume":"15","author":"Suissa","year":"2018","journal-title":"COPD"},{"issue":"1","key":"zoi240285r16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.7326\/0003-4819-157-1-201207030-00004","article-title":"Thirty-day rehospitalizations after acute myocardial infarction: a cohort study.","volume":"157","author":"Dunlay","year":"2012","journal-title":"Ann Intern Med"},{"issue":"3","key":"zoi240285r17","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1378\/chest.12-2313","article-title":"Impact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention.","volume":"144","author":"Campo","year":"2013","journal-title":"Chest"},{"issue":"10","key":"zoi240285r18","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.amjcard.2017.02.024","article-title":"Effect of chronic obstructive pulmonary disease on in-hospital mortality and clinical outcomes after ST-segment elevation myocardial infarction.","volume":"119","author":"Agarwal","year":"2017","journal-title":"Am J Cardiol"},{"key":"zoi240285r19","doi-asserted-by":"publisher","first-page":"f6650","DOI":"10.1136\/bmj.f6650","article-title":"Effect of \u00df blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records.","volume":"347","author":"Quint","year":"2013","journal-title":"BMJ"},{"issue":"3","key":"zoi240285r20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ccm.2020.06.002","article-title":"Multimorbidity in patients with chronic obstructive pulmonary disease.","volume":"41","author":"Divo","year":"2020","journal-title":"Clin Chest Med"},{"issue":"7","key":"zoi240285r21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236011","article-title":"Prediction of five-year mortality after COPD diagnosis using primary care records.","volume":"15","author":"Kiddle","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"zoi240285r22","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jacc.2016.05.049","article-title":"Predicting in-hospital mortality in patients with acute myocardial infarction.","volume":"68","author":"McNamara","year":"2016","journal-title":"J Am Coll Cardiol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2818870\/lafon_2024_oi_240285_1715284912.05601.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T15:07:24Z","timestamp":1716304044000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2818870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.7535","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]}}}